J&J's Janssen Gets Health Canada OK for Expanded Imbruvica Use

Date : 09/11/2019 @ 01:17
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 147.3  0.57 (0.39%) @ 10:00
Johnson and Johnson share price Chart
After Hours
Last Trade
Last $ 147.30 ◊ 0.00 (0.00%)

J&J's Janssen Gets Health Canada OK for Expanded Imbruvica Use

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

From Jun 2019 to Jun 2020

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said it received Health Canada approval of the cancer drug Imbruvica in combination with obinutuzumab for treatment-naive patients with active chronic lymphocytic leukemia, or CLL.

Janssen said the indication marks the first approval for a non-chemotherapy combination regimen for treatment-naive patients with CLL, one of the most common types of leukemia in adults.

It also marks the ninth indication for Imbruvica in Canada since its first approval in November 2014, Janssen said.

Imbruvica is commercialized in Canada by Janssen, which jointly develops the drug with AbbVie Inc.'s (ABBV) Pharmacyclics LLC.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

November 08, 2019 09:02 ET (14:02 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Euro vs Au..
US Dollar ..
BHP Bilito..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20200606 18:32:56